Elevise Diabetes Care has just started walking, despite inheriting a 70 -year history in the diabetes field.At the beginning of 2016, the sale of the Bayer Diabetes Care business was established - with all its products and services for the aforementioned disease - to Panasonic Healthcare Holdings.
It is backed with KKR investment firm funds and Panasonic Corporation."Both share our commitment to develop and grow the business, with a vision of the future and a more comprehensive approach to diabetes," Javier Benítez, general director of Elevise in Spain, explains to DM.He adds that "in the glucose meters sector, our company is the only one that belongs to a technology leader: Panasonic Healthcare Holdings."
Elevise and Panasonic Healthcare operate as independent companies, reporting both to the holding.The first offers products and solutions that make a positive difference in diabetics day to day, while Panasonic Healthcare develops, manufactures, sells and distributes medical material.
One of its main business areas, in Vitro Diagnostics, includes blood glucose monitoring systems and Point of Care.Another area, Medicom, develops computer systems for the use of health professionals and electronic clinical history, and its area of Life Sciences, Biomedical, works in dental material and bacterial count, among others.
The company seeks greater self -management of the patient disease, which responds to a need of both this and the system, which reduces costs
synergies
According to Benítez, both Elevise and Panasonic "are leading companies in the global diabetes care industry, and there are unique synergies between the two."Elevise has a strong presence in Europe, the Middle East, Asia and North America, and has extensive experience in the sale and distribution of medical equipment.Panasonic develops and manufactures medical material, and has a great presence in Japan.
Ascension products are sold in more than 125 countries, and after the closure of the transaction in all subsidiaries will have more than 1,400 employees and operations in 38 countries."In Spain, we have more than fifty people and our central offices are in Cornellà de Llobregat, Barcelona."The subsidiary has been growing over the market for the last years thanks to the launch of the contaur Next Reactive strip and the glucose meters of the Contour Next family.
Benítez indicates that innovation and research are a priority in the company."We have a very competitive pipeline, based on the development of really innovative research programs. One of our priority foci in R&D is to improve health results, going a step further through an interconnected management of diabetes, collection, collection,Analysis and interpretation of health data ".
"The transformation," he adds - will be progressive: we will evolve in a sustainable, solid and faithful way to our values. We are starting and we are very clear where we are going: we want to continue developing our product line with the aim of recognizing us as a leaderWorld Cup in high quality solutions. "
The company collaborates with health professionals and other fields "so that our products reach the highest standards of precision and accuracy, and help diabetics to handle the disease, regardless of the type or degree of evolution or frequency ofnecessary glucose controls. "
Its extensive portfolio allows to incorporate glucose measurement more easily into their daily life of patients, since it adapts to different needs."We are committed to followInvestigating, innovating and developing new products that improve the adherence and trust of people with diabetes.
active patient
Benítez recalls that the main challenge of diabetes management is to increase the active role of the patient, especially in the self -management of his illness.
"We have to respond to that need of both the patient and the health system, since numerous studies show that a greater self -management of diabetes reduces the risk of important complications derived from the disease, which in turn helps reduce costs forAdministration and can make our health system more sustainable. "
Specifically, the annual cost per person for the health system is 67 percent higher among diabetics.
The formula used for this is not limited to the development of glucose meters, but also of "innovative, relevant, future, safe and reliable solutions, which simplify the lives of patients and contribute to improve them," he concludes.
